Total: $1,063.07M

Company
(Symbol)#
(M)

Type Of Financing

Number Of
Shares, Units Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details (Date)@


Abgenix Inc.
(ABGX)

Private placement of convertible notes

N/A

$225

The 1.75% senior notes due in 2011 are convertible into common stock at $12.82 per share; purchasers have an option to buy another $75M of the notes (12/15)

Aradigm
Corp.
(ARDM)

Private placement of stock and warrants

8.3S and ND

$12.5

The shares were sold at $8.50 each, a discount of 16%; warrant details were not disclosed; SG Cowen was lead placement agent and Punk, Ziegel was co-agent for the deal (12/20)

Biomira Inc.
(BIOM)

Private placement of stock and warrants

4.89S and 0.978W

$12.57

The shares were sold from a shelf registration at $2.57 each, a 15% discount; the three- year warrants are exercisable at $3.45 per share; Rodman & Renshaw LLC was placement agent (12/9)

Biopure Corp.
(BPUR)

Private placement of stock and warrants

40S and 20W

$11.6

The company sold 40M shares at $0.29 each and 20M warrants exercisable at $0.31 per share from a shelf registration to institutional and individual investors; C.E. Unterberg, Towbin LLC was placement agent (12/9)

Bio-Rad
Laboratories
Inc.
(AMEX:BIO)

Private placement of notes

N/A

$200

The 6.125% senior subordinated notes are due in 2014 (12/13)

Cell
Therapeutics
Inc.
(CTIC)

Private placement of stock

2.586S

$18.5

The shares from a shelf registration were sold to institutional investors in a direct offering at $7.10 each (12/20)

Cortex
Pharmaceuticals
Inc.
(AMEX:COR)

Private placement of stock and warrants

4.233S and 2.117W

$11.26

New and existing institutional investors purchased the shares at $2.66 each; the five-year warrants are exercisable at $3 per share; Rodman & Renshaw LLC was placement agent (12/15)

DOV
Pharmaceutical
Inc.
(DOVP)

Private placement of convertible notes

N/A

$65

The convertible subordinated debentures due 2025 have an interest rate of 2.5%; the initial conversion price is $22.75 per share; investors have an option to purchase another $15M in notes (12/16)

Emisphere Inc. (EMIS)

Private placement of stock

N/A

$20

Kingsbridge Capital Ltd. committed to purchase up to $20M of Emisphere stock over two years; Emiisphere can sell shares equal to 3% of its market cap at discounts of 8% to 12%; Kingsbridge got a warrant to purchase 250,000 shares at a premium as part of the deal (12/28)

EntreMed
Inc.
(ENMD)

Private placement of stock and warrants

5.5S and 1.1W

$14

The shares were sold at $2.55 each; the five-year warrants are convertible at a 15% premium; Rodman & Renshaw LLC was placement agent; Ferghana Partners also participated (12/27)

Genitope
Corp.
(GTOP)

Private placement of stock

4.25S

$60.6

The shares were sold at $14.25 each in a private placement with institutional and accredited investors; WR Hambrecht + Co. LLC was placement agent (12/14)

Genta Inc.
(GNTA)

Private placement of stock

15S

$22.5

Genta agreed to sell two institutional investors the shares at $1.50 each, from a shelf registration; Rodman & Renshaw LLC was placement agent (12/15)

Halozyme
Therapeutics
Inc.
(AMEX:HTI)

Warrants exercise

1.57S

$2.75

Holders of warrants exercised them for the purchase of about 1.57M shares (12/15)

ID Biomedical
Corp.
(Canada;
IDBE)

Loan

N/A

$60

Second City Capital Partners provided the 8% loan that becomes due in 18 months; it also received two-year warrants to purchase 1.2M common shares at $16.91 per share (12/22)

Innovative
Drug Delivery
Systems Inc.
(OTC BB:ITRD)

Private placement of stock

6S

$18

The shares were sold at $3 each in conjunction with privately held IDDS' merger with Intrac Inc., under which IDDS was the surviving entity; Rodman & Renshaw was placement agent (12/7)

Introgen
Therapeutics
Inc.
(INGN)

Private placement of stock

0.975S

$7.8

The shares were sold from a shelf registration to the same European investors that participated in a financing two days earlier; Mulier Capital was placement agent (12/10)

Introgen
Therapeutics
Inc.
(INGN)

Private placement of stock

2.47S

$16.4

The shares were sold from a shelf registration; more than $15M of the total was placed with two European institutional investors; Mulier Capital was placement agent (12/8)

Lynx
Therapeutics
Inc.
(LYNX)

Bridge loan

N/A

$3

Silicon Valley Bank provided the facility, backed by Lynx's assets (12/30)

Millenium
Biologix Inc.
(Canada; TSE:
MBC)

Private placement of stock

5.45S

C$15 (US$12.4)

The shares were sold at C$2.75 each, a deal done in conjunction with its acquisistion of Cytovax Biotechnologies Inc.; RBC Capital Markets was lead agent in the financing, with Dlouhy Merchant Group Inc. as co-agent (12/3)

Mologen AG (Germany; FSE:MGNG)

Private placement of stock

0.55S

€1.16
(US$1.58)

Mologen issued the shares at €2.10 each against cash deposits of institutional investors (12/20)

Neoprobe
Corp.
(OTC BB:
NEOP)

Private placement of notes and warrants

N/A

$8.1

Great Point Partners LLC purchased $8M of the four-year, 8% notes that are convertible into stock at $0.40 per share; the warrants are exercisable for 10.125M shares at $0.46 per share (12/14)

NexMed
Inc.
(NEXM)

Private
placement of
stock and
warrants

5.495S and 2.75W

$7.03

The shares were sold at $1.28 each; five-year warrants to purchase 2.198M shares are exercisable at $1.47 per share; one-year warrants to purchase 549,536 shares are exercisable at $2 per share (12/22)

NPS
Pharmaceuticals
Inc.
(NPSP)

Private placement of notes

N/A

$175

The 8% notes were placed with institutional investors and are secured by revenues paid to NPS from sales of Sensipar, a drug licensed to and sold by Amgen Inc. (12/23)

Oncolytics
Biotech Inc.
(Canada; ONCY)

Warrants exercise

1.265S

$5.06

Investors in a June 2003 financing exercised warrants for about 1.265M shares (12/21)

OXIS
International
Inc.
(OTC BB:OXIS)

Private placement of stock and warrants

12.26S and 12.26W

$6.5

The shares were sold at $0.53 each; half the warrants are exercisable at $0.66 per share and half at $1 per share; Rodman & Renshaw LLC was placement agent (12/31)

Penwest
Pharmaceuticals
Co.
(PPCO)

Private placement of stock

3.125S

$35

The shares were sold to institutional and other investors at $11.20 each (12/10)

Peplin Ltd.
(Australia;
ASX:PEP)

Rights issue

24.3S

A$10.2
(US$7.8)

Shareholders purchased about 75% of the shares in the rights issue, which was fully underwritten by ABN AMRO Morgans and Wilson HTM (12/8)

Pharmaxis
Inc.
(Australia;
ASX:PXS)

Private placement and share purchase

26.36S

A$19.77 (US$15.1)

Pharmaxis placed 22M shares with institutions and other investors at A75 cents per share; separately, it will issue about 4.36M shares under a share purchase plan (12/14)

Physiomics
plc
(UK; AIM:PYC)

Private placement of stock

37.5S

£0.75 (US$1.45)

Physiomics sold the shares at 2 pence each, and with the deal began trading on the Alternative Investment Market (12/20)

Prana
Biotechnology
Ltd.
(Australia;
PRAN)

Exercise of options

9.5S

A$4.75 (US$3.6)

9.5M options that expired Dec. 1 were exercised for the purchase of one share at A$0.50 each (12/8)

Provectus
Pharmaceuticals
Inc.
(OTC BB:PVCT)

Private placement of stock and warrants

0.557S and 0.835W

$0.42

The shares were sold at $0.75 each and the warrants are exercisable at $1 per share; placement agent Venture Catalyst LLC received $41,762 in the deal (12/9)

Resverlogix
Corp.
(Canada;
VSE:RVX)

Bought-deal financing

1.027S

C$3.1 (US$2.55)

The initial 2.64M shares in the deal were issued in November; the shares were purchased by First Associates Investments Inc. and its syndicate comprised Haywood Securities Inc., Loewen Ondaatje McCutcheon Ltd., Sprott Securities Inc. and Jennings Capital Inc. (12/16)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.

No Comments